Filter your results
- 3
- 3
- 3
- 2
- 1
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.New England Journal of Medicine, 2019, 381 (21), pp.2020-2031. ⟨10.1056/NEJMoa1910231⟩
Journal articles
hal-02528435v1
|
||
|
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsClinical Cancer Research, 2019, 25 (11), pp.3220-3228. ⟨10.1158/1078-0432.CCR-18-2740⟩
Journal articles
hal-02528511v1
|
||
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsScience, 2018, 359 (6371), pp.91-97. ⟨10.1126/science.aan3706⟩
Journal articles
hal-02126484v1
|